Boston Scientific Seeks To Limit Embolization Device Adverse Event Focus
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific recommends that only serious, device- and procedure-related adverse events be defined during clinical testing of vascular and neurovascular embolization devices
You may also be interested in...
Neurovascular, Vascular Embolization Devices Shifting To Class II
FDA is adding vascular devices to its proposed recategorization of neurovascular embolization devices from Class III to Class II with special controls
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.